Log in

NASDAQ:AQSTAquestive Therapeutics Stock Price, Forecast & News

$4.71
-0.03 (-0.63 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.54
Now: $4.71
$4.82
50-Day Range
$4.74
MA: $5.31
$6.44
52-Week Range
$1.41
Now: $4.71
$10.00
Volume734,572 shs
Average Volume869,013 shs
Market Capitalization$158.18 million
P/E RatioN/A
Dividend YieldN/A
Beta3.6
Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors. It also develops AQST-119, an oral soluble film formulation of tadalafil for the treatment of erectile dysfunction; and APL-130277, a sublingual film using apomorphine to treat parkinson's disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.
Read More
Aquestive Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.71 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AQST
CUSIPN/A
CIKN/A
Phone908-941-1900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$52.61 million
Book Value($0.18) per share

Profitability

Net Income$-66,250,000.00
Net Margins-139.64%

Miscellaneous

Employees232
Market Cap$158.18 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive AQST News and Ratings via Email

Sign-up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.

Aquestive Therapeutics (NASDAQ:AQST) Frequently Asked Questions

How has Aquestive Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Aquestive Therapeutics' stock was trading at $2.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AQST shares have increased by 60.2% and is now trading at $4.71. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aquestive Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aquestive Therapeutics.

When is Aquestive Therapeutics' next earnings date?

Aquestive Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Aquestive Therapeutics.

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics Inc (NASDAQ:AQST) issued its quarterly earnings results on Tuesday, May, 5th. The company reported ($0.49) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.47) by $0.02. The firm earned $8.77 million during the quarter, compared to analysts' expectations of $10.90 million. View Aquestive Therapeutics' earnings history.

What guidance has Aquestive Therapeutics issued on next quarter's earnings?

Aquestive Therapeutics issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, May, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $35-45 million, compared to the consensus revenue estimate of $41.4 million.

What price target have analysts set for AQST?

5 brokerages have issued twelve-month target prices for Aquestive Therapeutics' shares. Their forecasts range from $8.00 to $31.00. On average, they expect Aquestive Therapeutics' stock price to reach $16.40 in the next twelve months. This suggests a possible upside of 248.2% from the stock's current price. View analysts' price targets for Aquestive Therapeutics.

Has Aquestive Therapeutics been receiving favorable news coverage?

Headlines about AQST stock have trended somewhat negative this week, InfoTrie reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aquestive Therapeutics earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Aquestive Therapeutics.

Who are some of Aquestive Therapeutics' key competitors?

What other stocks do shareholders of Aquestive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Inovio Pharmaceuticals (INO), AbbVie (ABBV), Alibaba Group (BABA), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Roku (ROKU), Aimmune Therapeutics (AIMT), Outlook Therapeutics (OTLK), Applied Genetic Technologies (AGTC) and Anavex Life Sciences (AVXL).

Who are Aquestive Therapeutics' key executives?

Aquestive Therapeutics' management team includes the following people:
  • Mr. Keith J. Kendall, CEO, Pres & Director (Age 62, Pay $859.98k)
  • Mr. John T. Maxwell, Sr. VP & CFO (Age 55, Pay $537.15k)
  • Mr. Daniel Barber, Sr. VP & COO (Age 44, Pay $639.97k)
  • Mr. Alexander Mark Schobel, Chief Innovation & Technology Officer (Age 61)
  • Ms. Lori J. Braender Esq., Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 64)

When did Aquestive Therapeutics IPO?

(AQST) raised $60 million in an initial public offering on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

What is Aquestive Therapeutics' stock symbol?

Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST."

How do I buy shares of Aquestive Therapeutics?

Shares of AQST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aquestive Therapeutics' stock price today?

One share of AQST stock can currently be purchased for approximately $4.71.

How big of a company is Aquestive Therapeutics?

Aquestive Therapeutics has a market capitalization of $158.18 million and generates $52.61 million in revenue each year. The company earns $-66,250,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis. Aquestive Therapeutics employs 232 workers across the globe.

What is Aquestive Therapeutics' official website?

The official website for Aquestive Therapeutics is www.aquestive.com.

How can I contact Aquestive Therapeutics?

Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The company can be reached via phone at 908-941-1900 or via email at [email protected]

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.